Cargando…

Case Report: Lack of Control of Diabetes and Weight Gain in a Patient on Initiation and Rechallenge of Therapy With Olanzapine

Detalles Bibliográficos
Autor principal:	Schwetschenau, Kristen H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2006
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437453/ https://www.ncbi.nlm.nih.gov/pubmed/16623611 http://dx.doi.org/10.18553/jmcp.2006.12.3.260

Ejemplares similares

Weight gain with olanzapine: Drug, gender or age?
por: Jain, Sanjay, et al.
Publicado: (2006)

The Effect of Ranitidine on Olanzapine-Induced Weight Gain
por: Ranjbar, Fatemeh, et al.
Publicado: (2013)

Olanzapine: Worsening of obsessive compulsive disorder and weight gain: case report
Publicado: (2022)

Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine
por: Fitzgerald, Ita, et al.
Publicado: (2021)

Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats
por: Hu, Yueshan, et al.
Publicado: (2014)

The Antipsychotic Olanzapine Interacts with the Gut Microbiome to Cause Weight Gain in Mouse
por: Morgan, Andrew P., et al.
Publicado: (2014)

Longitudinal Gut Microbiota Dysbiosis Underlies Olanzapine-Induced Weight Gain
por: Qian, Li, et al.
Publicado: (2023)

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
por: Sax, Paul E, et al.
Publicado: (2019)

Diazepam/olanzapine: Lack of efficacy and drowsiness: 2 case reports
Publicado: (2022)

Preventing Olanzapine-Induced Weight Gain Using Betahistine: A Study in a Rat Model with Chronic Olanzapine Treatment
por: Lian, Jiamei, et al.
Publicado: (2014)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
por: Okazaki, Kosuke, et al.
Publicado: (2017)

Weight gain as a secondary effect of Olanzapine, and its interference in treatment adherence: a case report.
por: Setién Preciados, P., et al.
Publicado: (2023)

Optimal gestational weight gain
por: Zhou, Yu-bo, et al.
Publicado: (2021)

Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain
por: Weston-Green, Katrina, et al.
Publicado: (2012)

Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia
por: Tsuneyama, Nobuto, et al.
Publicado: (2016)

Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review
por: Laguado, S. Andrea, et al.
Publicado: (2022)

Lack of Association between Glutathione S-Transferase-M1, -T1, and -P1 Polymorphisms and Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients
por: Park, Young-Min, et al.
Publicado: (2010)

Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient
por: Froudarakis, Marios E, et al.
Publicado: (2010)

Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats
por: Reynolds, Gavin P., et al.
Publicado: (2019)

Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats
por: Ashraf, Ghulam Md, et al.
Publicado: (2021)

Comment on “Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review”
por: Todtenkopf, Mark S., et al.
Publicado: (2023)

Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
por: Grywińska, Weronika B., et al.
Publicado: (2023)

Fat cell lipolysis and future weight gain
por: Nishizawa, Hitoshi, et al.
Publicado: (2018)

Unraveling the Mechanisms Underlying Olanzapine-Induced Insulin Resistance
por: Irwin, Nigel, et al.
Publicado: (2013)

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?
por: Metro, Giulio, et al.
Publicado: (2020)

Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
por: Cunningham, Jacobi I, et al.
Publicado: (2019)

Olanzapine-Induced Activation of Hypothalamic Astrocytes and Toll-Like Receptor-4 Signaling via Endoplasmic Reticulum Stress Were Related to Olanzapine-Induced Weight Gain
por: He, Meng, et al.
Publicado: (2021)

Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota
por: Kao, Amy Chia-Ching, et al.
Publicado: (2018)

Metformin Attenuates Liver Fat Content: Finding from Schizophrenia Patients with Olanzapine-induced Weight Gain
por: Wang, Li, et al.
Publicado: (2020)

Early Lipid Metabolic Effects of the Anti-Psychotic Drug Olanzapine on Weight Gain and the Associated Gene Expression
por: Chen, Chien-Chih, et al.
Publicado: (2022)

Hyponatremia after initiation and rechallenge with trimethoprim–sulfamethoxazole in an older adult
por: Huntsberry, Ashley M, et al.
Publicado: (2015)

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
por: Haanen, John, et al.
Publicado: (2020)

Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder
por: Lipkovich, Ilya, et al.
Publicado: (2008)

Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation
por: Fernø, Johan, et al.
Publicado: (2011)

Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
por: Huang, Jing, et al.
Publicado: (2020)

Olanzapine: Type-II diabetes mellitus: case report
Publicado: (2021)

In Pursuit of a Biomarker of Weight Gain Susceptibility—Is FGF21 a Candidate?
por: Redman, Leanne M., et al.
Publicado: (2019)

Dysphonia after Bevacizumab Rechallenge: A Case Report
por: Carter, Corey A., et al.
Publicado: (2015)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Lack of Ovarian Secretions Reverts the Anabolic Action of Olanzapine in Female Rats
por: Skrede, Silje, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lvd3sup3r4hei4v9g052hn9hl1